Gapping down
In reaction to disappointing earnings/guidance:
- AXDX -9.7%, NSTG -7.3%, NVTR -6.2%, CMC -6.1%, SIBN -5.6%, FOLD -5.1%, AMRN -4.9%, RTRX -4%, WMGI -3.9%, AMAG -3.7%, CSII -3.5%
M&A news:
- LLY -1% (to acquire LOXO for $8 bln)
Other news:
- SYRS -86.5% (outlines strategic priorities and expected milestones; Updated clinical data on SY-1425 in combination with Azacitidine expected in 2H19)
- HCLP -18.7% (provides Q4 operational and financial updates, Board suspends quarterly distribution)
- PCG -16.1% (Reuters report that the company is weighing a possible bankruptcy filing in the wake of the California wildfires)
- SNDX -13.8% (provides 2019 clinical and corporate outlook)
- NHTC -9% (responds to 'speculations and allegations falsely purported' against the Company in a segment that aired on January 5, 2019 on CCTV)
- VYGR -6.1% (provides update on AADC clinical program for Parkinson's disease -- Voyager to increase the size of RESTORE-1 Phase 2 trial and to conduct a similarly-sized RESTORE-2 Phase 3 trial)
- WMGI -3.9% (announces organizational changes)
- AMAG -3.7% (confirms PDUFA extension of Vyleesi)
- GTN -3.4% (to terminate the national advertising sales representation agreements that cover acquired Raycom stations)
- GME -1.4% (modestly pulling back following last week's 24% gain)
- CUE -1.2% (files for $150 mln mixed securities shelf offering )
Analyst comments:
- CRZO -6% (downgraded to Market Perform from Outperform at BMO Capital Markets)
- HAFC -2.2% (downgraded to Mkt Perform from Outperform at Raymond James)
- SNAP -0.5% (downgraded to Hold at Pivotal Research Group)
